This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Amira Barkal, MD, PhD
Principal Founder and Interim CEO at Pheast Therapeutics


Dr. Amira Barkal, MD, PhD, is Principal Founder and Interim CEO at Pheast Therapeutics, an immuno-oncology company founded in 2020 with origins in Irv Weissman’s lab at Stanford University. Dr. Barkal received her MD and PhD in Stem Cell Biology and Regenerative Medicine in the Medical Scientist Training Program at Stanford University School of Medicine in 2021. She completed her doctoral thesis in the laboratory of Professor Irving Weissman, where she studied mechanisms of macrophage tumor immunosurveillance and led the discovery that CD24 is a novel innate immune checkpoint in cancer. She is a leader in the field of innate immunity in cancer, and conducts research aimed at understanding the regulators of intratumoral macrophage function. Dr. Barkal also holds a position as Resident Physician in Internal Medicine at Brigham and Women’s Hospital at Harvard Medical School. She is a recipient of the Ruth L. Kirschstein Fellowship of the National Cancer Institute, the Harold M. Weintraub Award, and the Society of Immunotherapy of Cancer Young Investigator Award.

Agenda Sessions

  • Boosting Macrophage Appetites for Cancer Immunotherapy